How Does Retatrutide's Triple-Receptor Mechanism Work?

GLP-1 receptor agonism is the mechanism shared by every compound in this class, including semaglutide: it slows gastric emptying, increases satiety signaling, and promotes glucose-dependent insulin release. GIP receptor agonism, added in dual agonists like tirzepatide, further augments the insulin response and influences lipid metabolism.

Retatrutide adds a third target — the glucagon receptor — which is unusual because glucagon is more commonly associated with raising blood glucose, not lowering body weight. In the metabolic research context Retatrutide is studied in, glucagon receptor agonism is understood to increase basal metabolic rate and energy expenditure, working alongside (not against) the appetite-suppressing GLP-1/GIP effects. Published trial data has also documented reductions in hepatic steatosis and improved HbA1c in research populations, both areas actively studied to characterize this three-receptor combination.

This mechanism description reflects published preclinical and clinical trial literature (Coskun et al., Cell Metabolism 2022; Jastreboff et al., NEJM 2023) — it is provided as research background only and does not constitute a therapeutic claim or dosing guidance.